Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Lateral popliteal nerve block with ultrasound guidance.

Gray AT, Huczko EL, Schafhalter-Zoppoth I.

Reg Anesth Pain Med. 2004 Sep-Oct;29(5):507-9. No abstract available.

PMID:
15372402
2.

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates.

Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J.

Clin Microbiol Infect. 2003 Dec;9(12):1250-2. No abstract available.

3.
4.

In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates.

Valera L, Gradelski E, Huczko E, Washo T, Yigit H, Fung-Tomc J.

J Antimicrob Chemother. 2002 Jul;50(1):140-2. No abstract available.

PMID:
12096023
5.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci.

Clark J, Fung-Tomc JC, Minassian B, Tsai YH, Yang H, Huczko E, Kolek B, Chaniewski S, Ferraro C, Drain R, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):1108-11.

6.

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci.

Fung-Tomc JC, Clark J, Minassian B, Pucci M, Tsai YH, Gradelski E, Lamb L, Medina I, Huczko E, Kolek B, Chaniewski S, Ferraro C, Washo T, Bonner DP.

Antimicrob Agents Chemother. 2002 Apr;46(4):971-6.

7.

Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.

Fung-Tomc J, Gradelski E, Huczko E, Minassian B, Bonner DP.

Int J Antimicrob Agents. 2001 Jul;18(1):77-80.

PMID:
11463531
8.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
9.

Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.

Huczko E, Conetta B, Bonner D, Valera L, Stickle T, Macko A, Fung-Tomc J.

Int J Antimicrob Agents. 2000 Dec;16(4):401-5.

PMID:
11118848
10.

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, Washo T, Gradelski E, Valera L, Bonner DP.

Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6.

11.

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.

Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.

J Antimicrob Chemother. 2000 Apr;45(4):437-46.

PMID:
10747819
12.

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.

Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP.

Diagn Microbiol Infect Dis. 1999 Oct;35(2):163-7.

PMID:
10579098
13.

In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

Fung-Tomc JC, Huczko E, Minassian B, Bonner DP.

Antimicrob Agents Chemother. 1998 Feb;42(2):313-8. Erratum in: Antimicrob Agents Chemother 1998 Apr;42(4):993.

14.

The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol.

Mosse CA, Meadows L, Luckey CJ, Kittlesen DJ, Huczko EL, Slingluff CL, Shabanowitz J, Hunt DF, Engelhard VH.

J Exp Med. 1998 Jan 5;187(1):37-48.

15.

Alloreactive cytotoxic T lymphocytes focus on specific major histocompatibility complex-bound peptides.

Smith KD, Huczko E, Engelhard VH, Li YY, Lutz CT.

Transplantation. 1997 Jul 27;64(2):351-9.

PMID:
9256200
16.

Probing HLA-B7 conformational shifts induced by peptide-binding groove mutations and bound peptide with anti-HLA monoclonal antibodies.

Smith KD, Mace BE, Valenzuela A, Vigna JL, McCutcheon JA, Barbosa JA, Huczko E, Engelhard VH, Lutz CT.

J Immunol. 1996 Sep 15;157(6):2470-8.

PMID:
8805647
17.

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1996 May;40(5):1289-93.

18.

Identification of a graft versus host disease-associated human minor histocompatibility antigen.

den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, et al.

Science. 1995 Jun 9;268(5216):1476-80.

PMID:
7539551
19.

Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice.

Man S, Newberg MH, Crotzer VL, Luckey CJ, Williams NS, Chen Y, Huczko EL, Ridge JP, Engelhard VH.

Int Immunol. 1995 Apr;7(4):597-605.

PMID:
7547687
20.

Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides.

Fung-Tomc JC, Huczko E, Stickle T, Minassian B, Kolek B, Denbleyker K, Bonner D, Kessler R.

Antimicrob Agents Chemother. 1995 Feb;39(2):533-8.

21.

Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Fung-Tomc JC, Huczko E, Banville J, Ménard M, Kolek B, Gradelski E, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):394-9.

22.

In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.

Kessler RE, Fung-Tomc J, Kolek B, Minassian B, Huczko E, Gradelski E, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):380-5.

23.

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE.

Antimicrob Agents Chemother. 1995 Feb;39(2):295-300.

24.

Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.

Gradelski E, Fung-Tomc J, Huczko E, Kessler RE.

J Antimicrob Chemother. 1993 Nov;32 Suppl B:75-80.

PMID:
8150769
25.

Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling.

Huczko EL, Bodnar WM, Benjamin D, Sakaguchi K, Zhu NZ, Shabanowitz J, Henderson RA, Appella E, Hunt DF, Engelhard VH.

J Immunol. 1993 Sep 1;151(5):2572-87.

PMID:
8360479
26.

beta-Lactamase parameters of heterogeneously and homogeneously methicillin-resistant Staphylococcus aureus.

Gradelski E, Huczko E, Kessler RE, Bonner DP, Fung-Tomc J.

J Antimicrob Chemother. 1993 Mar;31(3):441-2. No abstract available.

PMID:
8486580
27.

Mass spectrometric analysis of peptides associated with the human class I MHC molecules HLA-A2.1 and HLA-B7 and identification of structural features that determine binding.

Engelhard VH, Appella E, Benjamin DC, Bodnar WM, Cox AL, Chen Y, Henderson RA, Huczko EL, Michel H, Sakaguichi K, et al.

Chem Immunol. 1993;57:39-62. Review. No abstract available.

PMID:
8260089
28.

In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.

Fung-Tomc J, Huczko E, Kolek B, Thater C, Kessler RE.

Antimicrob Agents Chemother. 1991 Dec;35(12):2652-4.

29.

Emergence of homogeneously methicillin-resistant Staphylococcus aureus.

Fung-Tomc J, Huczko E, Gradelski E, Denbleyker K, Bonner DP, Kessler RE.

J Clin Microbiol. 1991 Dec;29(12):2880-3.

30.

Inability of cephalothin testing to predict cefprozil susceptibility.

Fung-Tomc J, Stickle T, Doyle C, Huczko E, Kessler RE.

J Clin Microbiol. 1991 Nov;29(11):2643-7.

31.

Evidence for locally synthesized and clonally restricted immunoglobulin in the synovial fluid from rheumatoid arthritis patients.

Carpenter AB, Huczko E, Eisenbeis CH Jr, Kelly RH.

Clin Chim Acta. 1990 Dec 13;193(1-2):1-12.

PMID:
2073742
32.

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

Fung-Tomc J, Huczko E, Pearce M, Kessler RE.

Antimicrob Agents Chemother. 1988 Sep;32(9):1443-5.

Supplemental Content

Loading ...
Support Center